本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Inhibrx Biosciences

24.53
+0.26501.09%
成交量:2.51万
成交额:61.40万
市值:3.55亿
市盈率:0.22
高:24.76
开:24.53
低:24.14
收:24.26
数据加载中...
2024/06/03

超过5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2024/06/03

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/05/31

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/05/30

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/30

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/30

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/30

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/30

重要事件披露

Form 8-K - Current report
2024/05/30

交易所摘牌声明

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2024/05/29

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/05/24

重要事件披露

Form 8-K - Current report
2024/05/23

SEC问询函

Form CORRESP - Correspondence
2024/05/22

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/05/17

重要事件披露

Form 8-K - Current report
2024/05/10

重要事件披露

Form 8-K - Current report
2024/05/10

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/08

重要事件披露

Form 8-K - Current report
2024/05/07

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/04/25

SEC问询函

Form CORRESP - Correspondence
2024/03/27

关联方拟减持公告

Form 144 - Report of proposed sale of securities